-
1
-
-
0346994689
-
Duration of venous thromboembolism prophylaxis after surgery
-
Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest. 2003;124(Suppl):386S-392S.
-
(2003)
Chest
, vol.124
, Issue.SUPPL.
-
-
Kearon, C.1
-
2
-
-
77953667062
-
Venous thromboembolism after elective hip and knee replacemaent surgery
-
Haas S, LassenMR. Venous thromboembolism after elective hip and knee replacemaent surgery. EJHPP Pract. 2010;16:17-19.
-
(2010)
EJHPP Pract
, vol.16
, pp. 17-19
-
-
Haas, S.1
Lassen, M.R.2
-
3
-
-
84899469467
-
Dabigatran or Rivaroxaban Versus Other Anticoagulants for Thromboprophylaxis after Major Orthopedic Surgery: Systematic Review of Comparative Clinical-effectiveness and Safety
-
Ndegwa S, Moulton K, Arǵaez C. Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: Systematic review of comparative clinical-effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
-
(2009)
Ottawa: Canadian Agency for Drugs and Technologies in Health
-
-
Ndegwa, S.1
Moulton, K.2
Arǵaez, C.3
-
4
-
-
77952466576
-
Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement
-
Salazar CA, Malaga G, Malasquez G. Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement. Cochrane Database Syst Rev (Online). 2010;4:CD005981.
-
(2010)
Cochrane Database Syst Rev (Online)
, vol.4
-
-
Salazar, C.A.1
Malaga, G.2
Malasquez, G.3
-
5
-
-
84880408536
-
-
Norwegian Medicine Agency accessed May 2011
-
Norwegian Medicine Agency. Preparatomtale. http://www.legemiddel verket.no/custom/Preparatsok/prepSearch-80333.aspx (accessed May 2011).
-
Preparatomtale
-
-
-
7
-
-
43249093669
-
What is "quality of evidence" and why is it important to clinicians?
-
Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336:995-998.
-
(2008)
BMJ
, vol.336
, pp. 995-998
-
-
Guyatt, G.H.1
Oxman, A.D.2
Kunz, R.3
Vist, G.E.4
Falck-Ytter, Y.5
Schunemann, H.J.6
-
8
-
-
33644939196
-
Frequency and timing of clinical venous thromboembolism after major joint surgery
-
Bjornara BT,Gudmundsen TE, DahlOE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br. 2006;88:386-391.
-
(2006)
J Bone Joint Surg Br
, vol.88
, pp. 386-391
-
-
Bjornara, B.T.1
Gudmundsen, T.E.2
Dahlo, E.3
-
9
-
-
77956057713
-
A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty
-
Dahl OE, Quinlan DJ, Bergqvist D, Eikelboom JW. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost. 2010;8:1966-1975.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 1966-1975
-
-
Dahl, O.E.1
Quinlan, D.J.2
Bergqvist, D.3
Eikelboom, J.W.4
-
10
-
-
17544386944
-
The clinical course of deepvein thrombosis. Prospective long-term follow-up of 528 symptomatic patients
-
Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deepvein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82:423-428.
-
(1997)
Haematologica
, vol.82
, pp. 423-428
-
-
Prandoni, P.1
Villalta, S.2
Bagatella, P.3
-
11
-
-
0035344645
-
Trends in the incidence of venous stasis syndrome and venous ulcer: A 25-year population-based study
-
Heit JA, Rooke TW, Silverstein MD, et al. Trends in the incidence of venous stasis syndrome and venous ulcer: A 25-year population-based study. J Vasc Surg. 2001;33:1022-1027.
-
(2001)
J Vasc Surg
, vol.33
, pp. 1022-1027
-
-
Heit, J.A.1
Rooke, T.W.2
Silverstein, M.D.3
-
12
-
-
34147169563
-
Incidence and mortality of venous thrombosis: A population-based study
-
Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost. 2007;5:692-699.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 692-699
-
-
Naess, I.A.1
Christiansen, S.C.2
Romundstad, P.3
Cannegieter, S.C.4
Rosendaal, F.R.5
Hammerstrom, J.6
-
15
-
-
84880404573
-
-
Omr°adeplan for rehabilitering. Sørlandet sykehus HF
-
Prosjektgruppe hofte-og kneopererte. Omr°adeplan for rehabilitering. Sørlandet sykehus HF; 2010.
-
(2010)
Prosjektgruppe Hofte-og Kneopererte
-
-
-
16
-
-
84880443940
-
-
Norwegian Directorate of Health accessed 2011
-
Norwegian Directorate of Health. Innsatsstyrt finansiering 2010. http://helsedirektoratet.no/finansiering/isf/Sider/default.aspx (accessed 2011).
-
(2010)
Innsatsstyrt Finansiering
-
-
-
19
-
-
14944386624
-
Fondaparinux sodium compared with enoxaparin sodium: A cost-effectiveness analysis
-
Bjorvatn A, Kristiansen F. Fondaparinux sodium compared with enoxaparin sodium: A cost-effectiveness analysis. Am J Cardiovasc Drugs. 2005;5:121-130.
-
(2005)
Am J Cardiovasc Drugs
, vol.5
, pp. 121-130
-
-
Bjorvatn, A.1
Kristiansen, F.2
-
20
-
-
34147138285
-
Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs
-
R̈as̈anen P, Paavolainen P, Sintonen H, et al. Effectiveness of hip or knee replacement surgery in terms of quality-adjusted life years and costs. Acta Orthop. 2007;78:108-115.
-
(2007)
Acta Orthop
, vol.78
, pp. 108-115
-
-
R̈as̈anen, P.1
Paavolainen, P.2
Sintonen, H.3
-
21
-
-
7744231093
-
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis
-
Haentjens P, De Groote K, Annemans L. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis. Arch Orthop Trauma Surg. 2004;124: 507-517.
-
(2004)
Arch Orthop Trauma Surg
, vol.124
, pp. 507-517
-
-
Haentjens, P.1
De Groote, K.2
Annemans, L.3
-
22
-
-
0030638624
-
Automated computer interviews to elicit utilities: Potential applications in the treatment of deep venous thrombosis
-
Lenert LA, Soetikno RM. Automated computer interviews to elicit utilities: Potential applications in the treatment of deep venous thrombosis. J Am Med Inform Assoc. 1997;4:49-56.
-
(1997)
J Am Med Inform Assoc
, vol.4
, pp. 49-56
-
-
Lenert, L.A.1
Soetikno, R.M.2
-
23
-
-
0035669803
-
Representing uncertainty: The role of cost-effectiveness acceptability curves
-
Fenwick E, Claxton K, SculpherM. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779-787.
-
(2001)
Health Econ
, vol.10
, pp. 779-787
-
-
Fenwick, E.1
Claxton, K.2
Sculpher, M.3
-
25
-
-
17644409026
-
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial
-
Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. J Thromb Haemost. 2005;3:103-111.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 103-111
-
-
Eriksson, B.I.1
Dahl, O.E.2
Buller, H.R.3
-
26
-
-
57649123692
-
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
-
RE-MOBILIZE Writing Committee
-
RE-MOBILIZE Writing Committee, Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9.
-
(2009)
J Arthroplasty
, vol.24
, pp. 1-9
-
-
Ginsberg, J.S.1
Davidson, B.L.2
-
27
-
-
35449007749
-
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: TheRE-MODEL randomized trial
-
Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: TheRE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-2185.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 2178-2185
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
-
28
-
-
34548575058
-
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
-
Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-956.
-
(2007)
Lancet
, vol.370
, pp. 949-956
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
-
29
-
-
79953836474
-
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) A randomised, double-blind, non-inferiority trial
-
Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105:721-729.
-
(2011)
Thromb Haemost
, vol.105
, pp. 721-729
-
-
Eriksson, B.I.1
Dahl, O.E.2
Huo, M.H.3
-
30
-
-
33644867218
-
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
-
Eriksson BI, Borris L, Dahl OE, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4:121-128.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 121-128
-
-
Eriksson, B.I.1
Borris, L.2
Dahl, O.E.3
-
31
-
-
33751559902
-
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
-
Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374-2381.
-
(2006)
Circulation
, vol.114
, pp. 2374-2381
-
-
Eriksson, B.I.1
Borris, L.C.2
Dahl, O.E.3
-
32
-
-
45949103416
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
-
Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786.
-
(2008)
N Engl J Med
, vol.358
, pp. 2776-2786
-
-
Lassen, M.R.1
Ageno, W.2
Borris, L.C.3
-
33
-
-
34250651947
-
Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement
-
Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59-7939)-an oral, direct Factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res. 2007;120:685-693.
-
(2007)
Thromb Res
, vol.120
, pp. 685-693
-
-
Eriksson, B.I.1
Borris, L.C.2
Dahl, O.E.3
-
34
-
-
84886943075
-
Rivaroxaban for the prevention of venous thromboembolism: A single technology appraisal
-
Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Rivaroxaban for the prevention of venous thromboembolism: A single technology appraisal. Health Technol Assess. 2009;13(Suppl 3):43-48.
-
(2009)
Health Technol Assess
, vol.13
, Issue.SUPPL. 3
, pp. 43-48
-
-
Stevenson, M.1
Scope, A.2
Holmes, M.3
Rees, A.4
Kaltenthaler, E.5
-
35
-
-
65549169515
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial
-
Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): A randomised trial. Lancet. 2009;373:1673-1680.
-
(2009)
Lancet
, vol.373
, pp. 1673-1680
-
-
Turpie, A.G.1
Lassen, M.R.2
Davidson, B.L.3
-
36
-
-
46049106502
-
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial
-
Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial. Lancet. 2008;372:31-39.
-
(2008)
Lancet
, vol.372
, pp. 31-39
-
-
Kakkar, A.K.1
Brenner, B.2
Dahl, O.E.3
-
37
-
-
0346688755
-
Relationship between deep venous thrombosis and the postthrombotic syndrome
-
Kahn SR, Ginsberg JS. Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med. 2004;164:17-26.
-
(2004)
Arch Intern Med
, vol.164
, pp. 17-26
-
-
Kahn, S.R.1
Ginsberg, J.S.2
-
38
-
-
0036861679
-
Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States
-
BottemanMF, Caprini J, Stephens JM, et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther. 2002;24:1960-1986.
-
(2002)
Clin Ther
, vol.24
, pp. 1960-1986
-
-
Botteman, M.F.1
Caprini, J.2
Stephens, J.M.3
-
39
-
-
70349923899
-
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting
-
McCullagh L, Tilson L, Walsh C, Barry M. A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics. 2009;27:829-846.
-
(2009)
Pharmacoeconomics
, vol.27
, pp. 829-846
-
-
McCullagh, L.1
Tilson, L.2
Walsh, C.3
Barry, M.4
-
40
-
-
60449095843
-
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery
-
Wolowacz SE, Roskell NS, Maciver F, et al. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin Ther. 2009;31:194-212.
-
(2009)
Clin Ther
, vol.31
, pp. 194-212
-
-
Wolowacz, S.E.1
Roskell, N.S.2
Maciver, F.3
-
41
-
-
84880444061
-
Verbalvedtak 4 vedr
-
ReportNo.: BU-sak 41/2009
-
Oslo kommune.Verbalvedtak 4 vedr. hjemmetjenesten. 2009. ReportNo.: BU-sak 41/2009.
-
(2009)
Hjemmetjenesten
-
-
Kommune, O.1
-
43
-
-
4043081391
-
Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients
-
Offord R, Lloyd AC, Anderson P, Bearne A. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. Pharm World Sci. 2004;26:214-220.
-
(2004)
Pharm World Sci
, vol.26
, pp. 214-220
-
-
Offord, R.1
Lloyd, A.C.2
Anderson, P.3
Bearne, A.4
-
44
-
-
70350537133
-
Incidence and cost burden of post-thrombotic syndrome
-
Ashrani AA, Heit JA. Incidence and cost burden of post-thrombotic syndrome. J Thromb Thrombolysis. 2009;28:465-476.
-
(2009)
J Thromb Thrombolysis
, vol.28
, pp. 465-476
-
-
Ashrani, A.A.1
Heit, J.A.2
-
45
-
-
45949099359
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
-
Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.
-
(2008)
N Engl J Med
, vol.358
, pp. 2765-2775
-
-
Eriksson, B.I.1
Borris, L.C.2
Friedman, R.J.3
-
46
-
-
28444474155
-
BAY 59-7939: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
-
Turpie AG, Fisher WD, Bauer KA, et al. BAY 59-7939: An oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3:2479-2486.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 2479-2486
-
-
Turpie, A.G.1
Fisher, W.D.2
Bauer, K.A.3
|